A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
- Registration Number
- NCT01212991
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1717
- Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
- Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy
- Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bony disease
- No prior treatment with cytotoxic chemotherapy
- Asymptomatic or mildly symptomatic from prostate cancer
- Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
- Known or suspected brain metastasis or active leptomeningeal disease
- History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer
Open-Label Treatment Period:
The following inclusion criteria apply to patients receiving enzalutamide or placebo during double-blind treatment.
Eligible patients must meet all inclusion criteria.
- Received randomized double-blind treatment in PREVAIL;
- Open-label day 1 visit is within 6 months after this amendment is approved and becomes effective at the study site;
- Is willing to maintain androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist or has had a bilateral orchiectomy;
The exclusion criteria apply only to patients starting new treatment with enzalutamide after receiving placebo as randomized treatment. Each patient must not meet any of the following criteria:
- Has taken commercially available enzalutamide (Xtandi);
- Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
- Known or suspected brain metastasis or active leptomeningeal disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Enzalutamide Enzalutamide -
- Primary Outcome Measures
Name Time Method Overall Survival During study period (up to 3 years) Overall survival was defined as the time from randomization to death due to any cause. For patients who were alive at the time of the analysis data cutoff, overall survival was censored at the last date the patient was known to be alive or analysis data cutoff date, whichever was first. This included patients who were known to have died after the data analysis cutoff date. Patients with no post-baseline survival information were censored on the date of randomization.
Radiographic Progression-free Survival (rPFS) During study period (up to 20 months) Radiographic progression-free survival was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause within 168 days after treatment discontinuation, whichever was first. Radiographic disease progression was evaluated by CT scan or MRI and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using RECIST 1.1 for soft tissue disease and PCWG2 guidelines for bone disease. Patients who did not reach the endpoint were censored at their last assessment.
- Secondary Outcome Measures
Name Time Method Best Overall Soft Tissue Response During study period (up to 3 years) The best overall soft tissue objective response is defined as partial response \[PR\] or complete response \[CR\] while on study treatment based on investigator assessments of target, nontarget, and new lesions using RECIST 1.1. Soft tissue was assessed by CT or MRI at regularly scheduled visits. Only patients with measurable soft tissue disease (ie, at least 1 target lesion identified per RECIST 1.1) at screening are included in this analysis. All percentages are based on number of participants with measurable soft tissue disease at screening in each treatment group.
Time to Initiation of Cytotoxic Chemotherapy During study period (up to 3 years) The time to initiation of cytotoxic chemotherapy is defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for the treatment of prostate cancer for each patient. For patients who did not start cytotoxic chemotherapy at the time of the analysis data cutoff, time to initiation of cytotoxic chemotherapy was censored at the date of last assessment where no cytotoxic chemotherapy was indicated or at the analysis data cutoff date, whichever was first. Time to initiation of cytotoxic chemotherapy for patients with no postbaseline assessments was censored on the date of randomization.
Time to Prostate-specific Antigen (PSA) Progression During study period (up to 3 years) Time to PSA progression was defined as the time from randomization to date of first confirmed observation of PSA progression for each patient. For patients with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir was documented, and confirmed 3 or more weeks later. For patients with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above baseline was documented, and confirmed 3 or more weeks later. For patients who did not have confirmed PSA progression at the time of the analysis data cutoff, time to PSA progression was censored at the date of the last PSA assessment showing no evidence of confirmed PSA progression or the analysis data cutoff date, whichever was first. Time to PSA progression for patients with no postbaseline assessments was censored on the date of randomization.
Time to First Skeletal-related Event During study period (up to 3 years) Time to first skeletal-related event was defined as the time from randomization to the date of the first occurrence of a skeletal-related event for each patient. A skeletal-related event was defined as radiation therapy or surgery to bone for prostate cancer, pathological bone fracture, spinal cord compression, or initiation/change in antineoplastic therapy to treat bone pain from prostate cancer. Skeletal-related events were recorded at each scheduled and unscheduled study visit and during long-term follow-up if a skeletal-related event was not documented previously. Patients who did not have a skeletal-related event at the time of the analysis data cutoff were censored at the date of last assessment indicating no evidence of skeletal-related event. Patients with no postbaseline assessments were censored on the date of randomization.
Percentage of Patients With Prostate Specific Antigen (PSA) Response ≥ 50% During study period (up to 3 years) PSA response was defined as a ≥ 50% reduction in PSA from baseline to the lowest postbaseline PSA value and required confirmation by a consecutive assessment at least 3 weeks later. Patients were evaluable for PSA response rate if a patient had a PSA level measured at baseline and at least one postbaseline assessment.
Trial Locations
- Locations (261)
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
North County Oncology Medical Clinic, Inc
🇺🇸Oceanside, California, United States
Levine Cancer Institute - Main
🇺🇸Charlotte, North Carolina, United States
BJH Pharmacy
🇺🇸Saint Louis, Missouri, United States
Barnes-Jewish Hospital
🇺🇸Saint Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
Barnes-Jewish St. Peters Hospital
🇺🇸Saint Peters, Missouri, United States
Karmanos Cancer Institute Weisberg Cancer Treatment Center
🇺🇸Farmington Hills, Michigan, United States
Salzburger Universitatsklinikum
🇦🇹Salzburg, Austria
Levine Cancer Institute - Southpark
🇺🇸Charlotte, North Carolina, United States
Barnes-Jewish West County Hospital
🇺🇸Creve Coeur, Missouri, United States
UZ Leuven - University Hospital Gasthuisberg
🇧🇪Leuven, Belgium
St George Private Hospital
🇦🇺Kogarah, New South Wales, Australia
Cancer Centers of North Carolina
🇺🇸Raleigh, North Carolina, United States
The Mount Sinai Medical Center
🇺🇸New York, New York, United States
UT Southwestern Medical Center at Dallas
🇺🇸Dallas, Texas, United States
Sunshine Hospital
🇦🇺St Albans, Victoria, Australia
Ordination Dr. Fink
🇦🇹Salzburg, Austria
Levine Cancer Institute
🇺🇸Charlotte, North Carolina, United States
Charite-Universitaetsmedizin Berlin, Campus Benjamin Franklin
🇩🇪Berlin, Germany
Cabrini Hospital Malvern
🇦🇺Malvern,, Victoria, Australia
Medizinische Hochschule Hannover
🇩🇪Hannover, Niedersachsen, Germany
Universitaetsklinikum Carl Gustav Carus Dresden an der
🇩🇪Dresden, Germany
Universitaetsklinikum Heidelberg, Klinik Fuer Urologie
🇩🇪Heidelberg, Germany
Krankenhaus der Barmherzigen Schwestern Linz
🇦🇹Linz, Austria
The Ottawa Hospital Cancer Centre, General Campus
🇨🇦Ottawa, Ontario, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
🇨🇦Hamilton, Ontario, Canada
Universitaetsklinikum Muenster
🇩🇪Muenster, Germany
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
Institut Gustave Roussy
🇫🇷Villejuif, France
Martini-Klinik am UKE Gmbh
🇩🇪Hamburg, Germany
Universitaetsklinikum Tuebingen, Universitaetsklinik fuer Urologie
🇩🇪Tuebingen, Germany
London RegCancer Program, London Health Sciences Centre
🇨🇦London, Ontario, Canada
Urologikum Hamburg
🇩🇪Hamburg, Germany
Herlev Hospital
🇩🇰Herlev, Denmark
HIA Begin, Service de Medecine Interne et Oncologie
🇫🇷Saint-Mande, France
Universitaetsklinikum des Saarlandes
🇩🇪Homburg/Saar, Germany
Clinique Pasteur
🇫🇷Toulouse, France
Docrates Clinic
🇫🇮Helsinki, Finland
Roskilde Sygehus
🇩🇰Roskilde, Denmark
Azienda Ospedaliera San. Camillo Forlanini
🇮🇹Rome, Italy
Gangnam Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Hopital Europeen Georges Pompidou
🇫🇷Paris Cedex 15, France
Centre de Recherche Clinique
🇫🇷Saint Herblain Cedex, France
Institut de Cancerologie Lucien Neuwirth
🇫🇷Saint-Priest en Jarez, France
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Kliniken Nordoberpfalz AG, Klinikum Weiden
🇩🇪Weiden In Der Oberpfalz, Germany
Staedtisches Klinikum Braunschweig gGmbH
🇩🇪Braunschweig, Germany
Hospital del Mar
🇪🇸Barcelona, Spain
Keio University Hospital
🇯🇵Shinjyuku-ku, Tokyo, Japan
Assaf Harofe Medical Center
🇮🇱Beer Yaakov, Israel
Nippon Medical School Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
Chonnam National University Hwasun Hospital
🇰🇷Hwasun-eup, Hwasun-gun, Jeonnam, Korea, Republic of
Universitaetsklinikum Ulm
🇩🇪Ulm, Germany
Universitaetsklinikum Mannheim, Klinik fuer Urologie
🇩🇪Mannheim, Germany
Clínica Universidad de Navarra
🇪🇸Pamplona, Navarra, Spain
Samsung Medical Center
🇰🇷Gangnam-gu, Seoul, Korea, Republic of
Nagasaki University Hospital
🇯🇵Nagasaki-shi, Nagasaki, Japan
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
🇮🇹Orbassano, TO, Italy
Skane University Hospital
🇸🇪Malmo, Sweden
Bishops Wood Hospital
🇬🇧Northwood, Middlesex, United Kingdom
Division of Oncourology, National Cancer Institute
🇱🇹Vilnius, Lithuania
Orebro University Hospital
🇸🇪Orebro, Sweden
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Songpa-gu, Seoul, Korea, Republic of
Hospital Madrid Norte Sanchinarro
🇪🇸Madrid, Spain
Fakultna nemocnica s poliklinikou F.D. Roosevelta B. bystrica
🇸🇰Banska Bystrica, Slovakia
Karolinska University Hospital Solna
🇸🇪Stockholm, Sweden
Mount Vernon Hospital
🇬🇧Northwood, Middlesex, United Kingdom
Northern Centre for Cancer Care
🇬🇧Newcastle Upon Tyne, Tyne and Wear, United Kingdom
Complejo Hospitalario Universitario A Coruna
🇪🇸A Coruna, Spain
Royal Marsden Hospital
🇬🇧Sutton, Surrey, United Kingdom
Althaia Xarxa Asistencial Manresa
🇪🇸Manresa, Barcelona, Spain
Hospital Clinic i Provincial
🇪🇸Barcelona, Spain
Corporacio Sanitaria Parc Tauli
🇪🇸Sabadell(Barcelona), Spain
Clatterbridge Cancer Centre NHS Foundation Trust
🇬🇧Bebington, Wirral, Merseyside, United Kingdom
Hospital Vall d'Hebron
🇪🇸Barcelona, Spain
Sahlgrenska University Hospital
🇸🇪Gothenburg, Sweden
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Spain
Oxford University Hospitals NHS Trust
🇬🇧Oxford, Oxfordshire, United Kingdom
Clinical Investigations and Research Unit, Royal Sussex County Hospital
🇬🇧Brighton, East Sussex, United Kingdom
Edinburgh Cancer Centre
🇬🇧Edinburgh, United Kingdom
Keck Hospital of USC
🇺🇸Los Angeles, California, United States
Northwestern Memorial Hospital
🇺🇸Chicago, Illinois, United States
LAC&USC Medical Center
🇺🇸Los Angeles, California, United States
UCLA Clark Urology Clinic
🇺🇸Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
🇺🇸Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
🇺🇸Los Angeles, California, United States
Northwestern Medical Faculty Foundation
🇺🇸Chicago, Illinois, United States
Beth Israel Deaoness Medical Center
🇺🇸Boston, Massachusetts, United States
UPMC Presbyterian
🇺🇸Pittsburgh, Pennsylvania, United States
State healthcare institute
🇷🇺St-Petersburg, Russian Federation
North-Western State Medical University named after I.I.Mechnikov of the Ministry of Healthcare
🇷🇺St.-Petersburg, Russian Federation
Department of Urology, National University Hospital
🇸🇬Singapore, Singapore
Cancer Center Oncology Medical Group
🇺🇸La Mesa, California, United States
Brigham & Women's Hospital
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Levine Cancer Institute - University
🇺🇸Charlotte, North Carolina, United States
Levine Cancer Institute - Ballantyne
🇺🇸Charlotte, North Carolina, United States
Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine
🇺🇸Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
MUSC Urology Medical Specialty Associates, East Cooper Medical Arts Center 3rd Floor
🇺🇸Mount Pleasant, South Carolina, United States
Virginia Oncology Associates
🇺🇸Virginia Beach, Virginia, United States
University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States
Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
North Coast Cancer Institute
🇦🇺Port Macquarie, New South Wales, Australia
Prince of Wales Hospital
🇦🇺Randwick, New South Wales, Australia
Royal North Shore Hospital, Department of Medical Oncology
🇦🇺St Leonards, New South Wales, Australia
Australian Clinical Trials Pty Ltd
🇦🇺Wahroonga, New South Wales, Australia
Westmead Hospital
🇦🇺Westmead, New South Wales, Australia
Heart Care Partners
🇦🇺Auchenflower, Queensland, Australia
Icon Cancer Care Wesley
🇦🇺Auchenflower, Queensland, Australia
River City Pharmacy
🇦🇺Auchenflower, Queensland, Australia
Icon Cancer Care Chermside
🇦🇺Chermside, Queensland, Australia
University of Queensland Centre for Clinical Research (UQCCR)
🇦🇺Herston, Queensland, Australia
Nuclear Medicine and Imaging Department
🇦🇺Herston, Queensland, Australia
Icon Cancer Care South Brisbane
🇦🇺South Brisbane, Queensland, Australia
Icon Cancer Foundation
🇦🇺South Brisbane, Queensland, Australia
Adelaide Cancer Centre
🇦🇺Kurralta Park, South Australia, Australia
Mater Private Cardiology
🇦🇺South Brisbane, Queensland, Australia
APHS Pharmacy
🇦🇺Kurralta Park, South Australia, Australia
Ashford Cancer Centre Research
🇦🇺Kurralta park, South Australia, Australia
Bendigo Health, Bendigo Hospital
🇦🇺Bendigo, Victoria, Australia
Bendigo Health Medical Imaging
🇦🇺Bendigo, Victoria, Australia
MIA Box Hill Radiology
🇦🇺Box Hill, Victoria, Australia
Oncology Eastern Clinical Research Unit (ECRU)
🇦🇺Box Hill, Victoria, Australia
Eastern Health
🇦🇺Box Hill, Victoria, Australia
Pharmacy Department
🇦🇺Box Hill, Victoria, Australia
Cabrini Hospital Brighton
🇦🇺Brighton, Victoria, Australia
Monash Health Translation Precinct
🇦🇺Clayton, Victoria, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Barwon Health, Geelong Hospital
🇦🇺Geelong, Victoria, Australia
Austin Hospital
🇦🇺Heidelberg, Victoria, Australia
QEII Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
CHU de Quebec - L'Hotel-Dieu de Quebec
🇨🇦Quebec, Canada
Aalborg Hospital Nord
🇩🇰Aalborg, Denmark
Centre de recherche clinique el evaluative en oncologie (CRCEO)
🇨🇦Quebec, Canada
Rigshospitalet
🇩🇰Copenhagen, Denmark
Institut Bergonie
🇫🇷Bordeaux, France
Centre Eugene Marquis-Service d'Oncologie Medicale
🇫🇷Rennes cedex, Bretagne, France
ICO Paul Papin
🇫🇷Angers, France
Clinique Rhone Durance
🇫🇷Avignon, France
CHD Vendee
🇫🇷La Roche sur Yon Cedex, France
Centre Jean Bernard - Clinique Victor Hugo
🇫🇷Le Mans, France
Centre Leon Berard
🇫🇷Lyon, France
Institut Curie
🇫🇷Paris, France
Groupe Hospitalier La Pitie Salpetriere
🇫🇷Paris, France
University Medical Center Groningen, Department of Urology
🇳🇱Groningen, Netherlands
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Pomorskie, Poland
Niepubliczny Zaklad Opieki Zdrowotnej
🇵🇱Myslowice, Slaskie, Poland
Singapore General Hospital
🇸🇬Singapore, Singapore
CUIMED s.r.o.
🇸🇰Bratislava, Slovakia
UROEXAM, spol. s r.o. urologicka ambulancia
🇸🇰Nitra, Slovakia
Poliklinika Sekcov, wesper, s.r.o.
🇸🇰Presov, Slovakia
Hospital Universitario German Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Medical Oncology Associates-SD
🇺🇸San Diego, California, United States
Sharp Memorial Hospital Investigational Pharmacy
🇺🇸San Diego, California, United States
Sharp Rees-Stealy
🇺🇸San Diego, California, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Investigational Chemotherapy Services
🇺🇸Durham, North Carolina, United States
Manitoba Prostate Centre
🇨🇦Winnipeg, Manitoba, Canada
Aarhus Universitetshospital
🇩🇰Aarhus N, Denmark
Frederiksberg Hospital
🇩🇰Frederiksberg, Denmark
Azienda Socio Sanitaria Territoriale di Cremona
🇮🇹Cremona, CR, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
🇮🇹Meldola, FC, Italy
Azienda USL8-Presidio Ospedaliero S.Donato
🇮🇹Arezzo, Italy
Ospedale G.B. Morgagni
🇮🇹Forli, Italy
Umea University Hospital
🇸🇪Umea, Sweden
University College London Hospital NHS Trust
🇬🇧London, United Kingdom
University Hospitals Bristol NHS Foundation Trust
🇬🇧Bristol, United Kingdom
Imperial College Healthcare NHS Trust
🇬🇧London, United Kingdom
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
National Cancer Center
🇰🇷Goyang, Gyeonggi-do, Korea, Republic of
Cancer Care SA Pty Ltd
🇦🇺Kurralta Park, South Australia, Australia
Sydney Adventist Hospital
🇦🇺Sydney, New South Wales, Australia
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Anschutz Cancer Center Pavilion Pharmacy
🇺🇸Aurora, Colorado, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Nebraska Methodist Hospital
🇺🇸Omaha, Nebraska, United States
University of Colorado Hospital, Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Portland VA Medical Center Laboratory
🇺🇸Portland, Oregon, United States
Lynn Cancer Institute Center for Hematology Oncology
🇺🇸Boca Raton, Florida, United States
Stanford University Medical Center
🇺🇸Stanford, California, United States
Showa University Hospital
🇯🇵Shinagawa-ku, Tokyo, Japan
UC Davis Medical Center
🇺🇸Sacramento, California, United States
University of California Davis Comprehensive Cancer Center
🇺🇸Sacramento, California, United States
Jewish Hospital & St. Mary's Healthcare, Inc.
🇺🇸Louisville, Kentucky, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Hopital Civil
🇫🇷Strasbourg, Alsace, France
Bnai Zion Medical Center
🇮🇱Haifa, Israel
Kindai University Hospital
🇯🇵Osaka-sayama, Osaka, Japan
Osaka International Cancer Institute
🇯🇵Osaka-shi, Osaka, Japan
Chiba Cancer Center
🇯🇵Chiba, Japan
Yamagata Prefectural Central Hospital
🇯🇵Yamagata, Japan
Vrije Universiteit Medical Center, Department of Medical Oncology
🇳🇱Amsterdam, Netherlands
The University of Arizona Cancer Certer-North Campus
🇺🇸Tucson, Arizona, United States
Nihon University Itabashi Hospital
🇯🇵Itabashi-ku, Tokyo, Japan
Velindre Cancer Centre
🇬🇧Cardiff, Wales, United Kingdom
Vancouver Island Health Authority-Royal Jubilee Hospital Medical Imaging
🇨🇦Victoria, British Columbia, Canada
Jessaziekenhuis
🇧🇪Hasselt, Belgium
Helsinki University Central Hospital
🇫🇮Helsinki, Finland
Tampere University Hospital
🇫🇮Tampere, Finland
Yamaguchi University Hospital
🇯🇵Ube-shi, Yamaguchi, Japan
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Tramatologii im. M.Kopernika w Lodzi
🇵🇱Lodz, Lodzkie, Poland
Tom Baker Cancer Centre - Holy Cross Site
🇨🇦Calgary, Alberta, Canada
British Columbia Cancer Agency, Sindi Ahluwalia Hawkins, Centre for the Southern Interior
🇨🇦Kelowna, British Columbia, Canada
AZ Groeninge, Campus KL
🇧🇪Kortrijk, Belgium
Oulu University Hospital
🇫🇮Oulu, Finland
Rabin Medical Center
🇮🇱Petach Tikva, Israel
Kyoto University Hospital
🇯🇵Kyoto, Japan
UMC St. Radboud
🇳🇱Nijmegen, Netherlands
UROCENTRUM MILAB s.r.o.
🇸🇰Presov, Slovakia
The University of Arizona Cancer Center-North Campus
🇺🇸Tucson, Arizona, United States
Kyorin University Hospital
🇯🇵Mitaka-shi, Tokyo, Japan
Centre Hospitalier Universitaire de Liege-Urologie
🇧🇪Liege, Belgium
Centre Hospitalier de l'Universite de Montreal
🇨🇦Montreal, Quebec, Canada
Kyushu University Hospital
🇯🇵Fukuoka-shi, Fukuoka, Japan
Osaka University Hospital
🇯🇵Suita-shi, Osaka, Japan
Tokushima University Hospital
🇯🇵Tokushima-shi, Tokushima, Japan
Cancer Institute Hospital
🇯🇵Koutou-ku, Tokyo, Japan
British Columbia Cancer Agency - Vancouver Island Centre
🇨🇦Victoria, British Columbia, Canada
Klaipeda University Hospital
🇱🇹Klaipeda, Lithuania
Catharina Ziekenhuis
🇳🇱Eindhoven, Netherlands
EMC Instytut Medyczny S.A.
🇵🇱Wroclaw, Dolnoslaskie, Poland
Wielkopolskie Centrum Onkologii
🇵🇱Poznan, Wielkopolskie, Poland
State Educational Institution of Higher Professional Education
🇷🇺St-Petersburg, Russian Federation
Univerzitna Nemocnica Martin
🇸🇰Martin, Slovakia
Alberta Health Services - Cancer Care, Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Vancouver Prostate Centre
🇨🇦Vancouver, British Columbia, Canada
Russian Academy of Medical Sciences Institution
🇷🇺Moscow, Russian Federation
Medizinische Universitaet Wien
🇦🇹Wien, Austria
AZ Sint-Lucas
🇧🇪Ghent, Belgium
Soroka University Medical Center
🇮🇱Beer Sheva, Israel
The Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Yokohama City University Hospital
🇯🇵Yokohama-shi, Kanagawa-ken, Japan
Tohoku University Hospital
🇯🇵Sendai-Shi, Miyagi, Japan
Niigata University Medical and Dental Hospital
🇯🇵Niigata, Japan
Osaka City University Hospital
🇯🇵Osaka, Japan
Jikei University Hospital
🇯🇵Tokyo, Japan
Apteka Szpitalna
🇵🇱Gdansk, Pomorskie, Poland
QEII Health Sciences Centre, Nova Scotia Cancer Centre.
🇨🇦Halifax, Nova Scotia, Canada
Hospital Son Espases
🇪🇸Palma de Mallorca, Islas Baleares, Spain
Hematology / Oncology MUSC Hollings Cancer Center
🇺🇸Charleston, South Carolina, United States
Medical University of South Carolina - Urology Services
🇺🇸Charleston, South Carolina, United States
MUSC Department of Radiology
🇺🇸Charleston, South Carolina, United States
MUSC Urology Ambulatory Care
🇺🇸Charleston, South Carolina, United States
SAN Radiology
🇦🇺Wahroonga, New South Wales, Australia
Cabrini Radiology
🇦🇺Malvern, Victoria, Australia
MUSC Hematology / Oncology Medical Specialty Associates, East Cooper Medical Arts Center 3rd Floor
🇺🇸Mount Pleasant, South Carolina, United States
Lismore Base Hospital, Lismore Cancer Care and Haematology Unit
🇦🇺Lismore, New South Wales, Australia
Calvary Mater Newcastle
🇦🇺Waratah, New South Wales, Australia
MDI Chemer
🇦🇺Malvern, Victoria, Australia
SAN Pathology
🇦🇺Wahroonga, New South Wales, Australia
Guy's and St Thomas' NHS Foundation Trust
🇬🇧London, United Kingdom